MedPath

Cefadroxil

Generic Name
Cefadroxil
Drug Type
Small Molecule
Chemical Formula
C16H17N3O5S
CAS Number
50370-12-2
Unique Ingredient Identifier
Q525PA8JJB
Background

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Indication

For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes

Associated Conditions
Bacterial Infections, Infection and inflammatory reaction due to internal prosthetic device, implant, and graft, Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Tonsillitis streptococcal, Urinary Tract Infection
Clinical Trials
Related News

FDA Approves FoundationOne CDx as Companion Diagnostic for Tovorafenib in Pediatric Low-Grade Glioma

• The FDA has approved FoundationOne CDx as a companion diagnostic for tovorafenib (Ojemda) in pediatric low-grade glioma (pLGG) patients with specific BRAF alterations. • FoundationOne CDx detects BRAF fusions, rearrangements, and V600 mutations, enabling precise identification of pLGG patients who may benefit from tovorafenib treatment. • Tovorafenib received accelerated approval in April 2024 for relapsed/refractory BRAF-altered pLGG, supported by a 67% overall response rate in the FIREFLY-1 trial. • This approval marks Foundation Medicine’s first companion diagnostic indication exclusively supporting pediatric patients, enhancing precision medicine in pediatric oncology.

Tempus Launches FDA-Approved xT CDx Test Nationwide for Comprehensive Solid Tumor Profiling

• Tempus AI has commercially launched xT CDx, an FDA-approved 648-gene NGS-based diagnostic test for solid tumor profiling, offering comprehensive genomic insights across multiple cancer types. • The test serves as a companion diagnostic for identifying KRAS wild-type colorectal cancer patients suitable for cetuximab treatment and KRAS/NRAS wild-type patients for panitumumab therapy. • Clinical validation demonstrated exceptional accuracy with 98.9% positive percent agreement and 100% negative percent agreement in hotspot variant detection across 416 tumor samples.

Precision Medicine and Value-Based Cancer Care: Navigating Implementation Challenges in Academic and Community Settings

• Precision medicine adoption in oncology faces distinct challenges in academic and community settings, with issues ranging from workflow variations to bureaucratic constraints in implementing biomarker testing. • Texas Oncology's implementation of cloud-based technology has improved clinical trial matching and patient tracking, while a new state law mandates insurance coverage for NGS testing in metastatic solid tumors. • Multiple myeloma treatment has evolved to include quadruplet therapies and CAR T-cell therapy, with MRD testing emerging as a valuable tool for treatment decision-making and value-based care alignment.

Allarity Therapeutics Advances Stenoparib for Ovarian Cancer with Phase 2 Trial Expansion

• Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection. • The trial focuses on patients with platinum-resistant disease who have shown durable clinical benefit from stenoparib in earlier phases. • Enrollment for the expanded Phase 2 trial is set to begin in the first half of 2025 at leading U.S. trial sites, with potential UK sites. • Stenoparib's impact on the Wnt pathway will be evaluated, potentially differentiating it in the PARP inhibitor market.

Lyme Disease Treatment Trials: Generalizability Concerns Highlighted

• A review questions the broad applicability of chronic Lyme disease treatment trials due to patient selection criteria. • The original study's population had long-term illness and multiple prior treatments, unlike many typical Lyme patients. • Exclusion of patients with early-stage chronic Lyme or those never treated limits the trial's generalizability. • The analysis suggests caution in applying trial results to all chronic Lyme disease patients, especially regarding antibiotic treatment.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy